Skip to main content

Advertisement

Table 1 Patient characteristics

From: Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation

  Patients without   Patients with  
  post-transplant adverse events
  n = 13   n = 48  
  No. [%] No. [%]
Sex     
 Male 7 (53.8) 29 (60.4)
 Female 6 (46.2) 19 (39.6)
Age group     
 <6 y 6 (46.2) 15 (31.3)
 6–12 y 3 (23.1) 18 (37.5)
 13–26 y 4 (30.8) 15 (31.3)
Donor     
 MUD 3 (23.1) 13 (27.1)
 MMFD 7 (53.8) 31 (64.6)
 MFD 1 (7.7) 4 (8.3)
 Autologous 2 (15.4) 0 (0.0)
Primary diagnosis     
 ALL 1 (7.7) 11 (22.9)
 ALL relapse 0 (0.0) 11 (22.9)
 AML 0 (0.0) 3 (6.3)
 AML relapse 1 (7.7) 4 (8.3)
 CML 1 (7.7) 2 (4.2)
 JMML 1 (7.7) 1 (2.1)
 MDS 0 (0.0) 4 (8.3)
 T-NHL 0 (0.0) 1 (2.1)
 Solid tumors 3 (23.1) 3 (6.3)
 Aplastic anemia 0 (0.0) 1 (2.1)
 Neurometabolic disease 1 (7.7) 3 (6.3)
 Immunologic disease 2 (15.4) 3 (6.3)
 Autoimmune disease 2 (15.4) 0 (0.0)
 Chédiak-Higashi syndrome 1 (7.7) 0 (0.0)
 Kostmann disease 0 (0.0) 1 (2.1)
 Neurologic disease 0 (0.0) 0 (0.0)
Radiation     
 TLI 0 (0.0) 3 (6.3)
 TBI 1 (7.7) 7 (14.6)
GvHD prophylaxis     
 CsA + MTX 3 (23.1) 11 (22.9)
 CsA 1 (7.7) 6 (12.5)
Acute GvHD     
 Grade I 0 (0.0) 11 (22.9)
 Grade II 0 (0.0) 9 (18.8)
 Grade III 0 (0.0) 3 (6.3)
 Grade IV 0 (0.0) 1 (2.1)
  1. Abbreviations: ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, CML chronic myeloid leukemia, CsA cyclosporine A, GvHD graft-versus-host disease, JMML juvenile myelomonocytic leukemia, MDS myelodysplastic syndromes, MFD matched family donor, MMFD mismatched family donor, MTX methotrexate, MUD matched unrelated donor, TBI total body irradiation, TLI total lymphoid irradiation, T-NHL T cell non-Hodgkin’s lymphoma, y year(s)